MX387397B - Régimen de dosificación para el tratamiento de tumores sólidos. - Google Patents
Régimen de dosificación para el tratamiento de tumores sólidos.Info
- Publication number
- MX387397B MX387397B MX2019002066A MX2019002066A MX387397B MX 387397 B MX387397 B MX 387397B MX 2019002066 A MX2019002066 A MX 2019002066A MX 2019002066 A MX2019002066 A MX 2019002066A MX 387397 B MX387397 B MX 387397B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- solid tumors
- dosage regimen
- oxo
- administering
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title 1
- YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona un régimen de dosificación, el cual comprende administrar la 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hidroxi-etil)-6-oxo-7H-pirido-[2,3-d][3]-benzazepin-7-il]-amino]-1-metil-2-oxo-etil]-butanamida o una sal farmacéuticamente aceptable o hidrato de la misma, para el tratamiento de un cáncer de tumor sólido en una dosis de carga especificada durante un período de dosificación definido, seguida por una dosis de mantenimiento y, de una forma opcional, administrar un corticosteroide durante la administración de la dosis de carga.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381911P | 2016-08-31 | 2016-08-31 | |
| PCT/US2017/048308 WO2018044662A1 (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002066A MX2019002066A (es) | 2019-06-03 |
| MX387397B true MX387397B (es) | 2025-03-18 |
Family
ID=59772787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002066A MX387397B (es) | 2016-08-31 | 2017-08-24 | Régimen de dosificación para el tratamiento de tumores sólidos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190209581A1 (es) |
| EP (1) | EP3506905B1 (es) |
| JP (2) | JP2019526632A (es) |
| KR (1) | KR102512899B1 (es) |
| CN (2) | CN116473978A (es) |
| AU (1) | AU2017321011B2 (es) |
| BR (1) | BR112019002461A2 (es) |
| CA (1) | CA3035616A1 (es) |
| ES (1) | ES2977556T3 (es) |
| IL (2) | IL305136A (es) |
| MA (1) | MA46086A (es) |
| MX (1) | MX387397B (es) |
| SG (2) | SG11201901325UA (es) |
| WO (1) | WO2018044662A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| KR102418765B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| KR102418766B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 |
| US10688104B2 (en) | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US46206A (en) | 1865-02-07 | Improved vessel for holding petroleum | ||
| US8633179B2 (en) * | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| HUE038452T2 (hu) * | 2007-11-13 | 2018-10-29 | Meritage Pharma Inc | Gyomor és bélrendszeri gyulladások kezelésére szolgáló kompozíciók |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| BR112017000130A2 (pt) * | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
-
2017
- 2017-08-24 US US16/328,267 patent/US20190209581A1/en not_active Abandoned
- 2017-08-24 IL IL305136A patent/IL305136A/en unknown
- 2017-08-24 MX MX2019002066A patent/MX387397B/es unknown
- 2017-08-24 CA CA3035616A patent/CA3035616A1/en active Pending
- 2017-08-24 KR KR1020197005847A patent/KR102512899B1/ko active Active
- 2017-08-24 EP EP17761723.0A patent/EP3506905B1/en active Active
- 2017-08-24 IL IL264924A patent/IL264924B2/en unknown
- 2017-08-24 JP JP2019531873A patent/JP2019526632A/ja active Pending
- 2017-08-24 ES ES17761723T patent/ES2977556T3/es active Active
- 2017-08-24 AU AU2017321011A patent/AU2017321011B2/en not_active Ceased
- 2017-08-24 SG SG11201901325UA patent/SG11201901325UA/en unknown
- 2017-08-24 MA MA046086A patent/MA46086A/fr unknown
- 2017-08-24 CN CN202310314953.4A patent/CN116473978A/zh active Pending
- 2017-08-24 WO PCT/US2017/048308 patent/WO2018044662A1/en not_active Ceased
- 2017-08-24 BR BR112019002461A patent/BR112019002461A2/pt not_active Application Discontinuation
- 2017-08-24 SG SG10202107832UA patent/SG10202107832UA/en unknown
- 2017-08-24 CN CN201780052146.2A patent/CN109562114A/zh active Pending
-
2022
- 2022-12-27 JP JP2022209634A patent/JP2023052108A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG10202107832UA (en) | 2021-09-29 |
| MX2019002066A (es) | 2019-06-03 |
| IL264924A (es) | 2019-04-30 |
| KR20190042591A (ko) | 2019-04-24 |
| EP3506905A1 (en) | 2019-07-10 |
| ES2977556T3 (es) | 2024-08-26 |
| MA46086A (fr) | 2019-07-10 |
| IL264924B1 (en) | 2023-09-01 |
| CN116473978A (zh) | 2023-07-25 |
| US20190209581A1 (en) | 2019-07-11 |
| SG11201901325UA (en) | 2019-03-28 |
| WO2018044662A1 (en) | 2018-03-08 |
| JP2019526632A (ja) | 2019-09-19 |
| BR112019002461A2 (pt) | 2019-05-14 |
| CN109562114A (zh) | 2019-04-02 |
| CA3035616A1 (en) | 2018-03-08 |
| AU2017321011B2 (en) | 2023-08-03 |
| KR102512899B1 (ko) | 2023-03-23 |
| AU2017321011A1 (en) | 2019-02-21 |
| IL264924B2 (en) | 2024-01-01 |
| JP2023052108A (ja) | 2023-04-11 |
| EP3506905B1 (en) | 2024-03-20 |
| IL305136A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019002461A2 (pt) | regime de dosagem para tratamento de tumores sólidos | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| EA202092671A1 (ru) | Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
| MX2009007597A (es) | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| MX388093B (es) | Dosis y regimen para inhibidores de la interaccion hdm2-p53. | |
| JP2022505041A5 (es) | ||
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| RU2018138626A (ru) | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака | |
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| EA201891289A1 (ru) | Циклическая терапия с применением 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона |